Drugs / AS01B

Trials 2 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04026009 Aug 2019 → May 2022 Clostridium infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00358332 Nov 2006 → Dec 2007 Plasmodium falciparum malaria U.S. Army Medical Research and Development Command Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03547245 Comparator Jun 2018 → Jan 2020 HIV infectious disease International AIDS Vaccine Initiative Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT03707808 Background Jan 2018 → Dec 2025 overdue malignant soft tissue neoplasm University Hospital Brussels Recruiting No outcome recorded
Phase 1/2 NCT02044198 Comparator Mar → Dec 2014 Plasmodium falciparum malaria University of Oxford Completed No outcome recorded
Phase 1/2 NCT01157897 Background Jul 2010 → Jan 2012 Plasmodium vivax malaria U.S. Army Medical Research and Development Command Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as AS01B “Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01BNCT01157897
4

NCT02044198

NCT03547245

NCT03707808

NCT04026009

Known as FMP2.1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02044198
1

NCT00358332

Known as FMP2.1/AS02(A) “The malaria vaccine FMP2.1/AS02(A) is a recombinant protein (FMP2.1) based on apical membrane antigen 1 (AMA1) from the 3D7 clone of P. falciparum, formulated in the Adjuvant...” PMID 20140214 Feb 2010
Modality Protein / enzyme biologic “The malaria vaccine FMP2.1/AS02(A) is a recombinant protein (FMP2.1) based on apical membrane antigen 1 (AMA1) from the 3D7 clone of P. falciparum, formulated in the Adjuvant...” PMID 20140214 Feb 2010
Route Intramuscular “administered by intramuscular injection” NCT00358332